Clinical Trial Update: ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy [Phase 2]

View source ↗

Summary

This clinical trial update describes a phase 2 study in which ctDNA monitoring guides the use of Befotertinib plus radiotherapy for advanced oligometastatic non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination | Phase 2 | Status: NOT_YET_RECRUITING